Vildagliptin is an oral anti-hyperglycemic agent of the new dipeptidyl peptidase-4 inhibitor class of drugs More
Vildagliptin is an oral anti-hyperglycemic agent of the new dipeptidyl peptidase-4 inhibitor class of drugs
Vildagliptin
Vildagliptin; Galvus; Xiliarx; Jalra
Galvus, Galvusmet, Jalra, Jalra-M, Zomelis, Zomelis-Met
(2S)-1-{2-[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile
Absorbed by oral, >90% oral bioavailability.
It is an oral antidiabetic agent, appears to be safe, very well tolerated, and efficacious. Following a meal, gut incretin hormones are released. The most important incretion hormones are GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). These hormones, secreted in the human small intestine, are responsible for insulin release due to increased glucose levels. This drug enhance the ability of GLP-1's to produce insulin in response to elevated concentrations of blood glucose, slow the rate of nutrient absorption into the bloodstream, inhibit the release of glucagon following meals, slow the rate of gastric emptying, and reduce food intake. Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4). This in turn inhibits the inactivation of GLP-1 by DPP-4, allowing GLP-1 to potentiate the secretion of insulin in the beta cells.
50mg twice daily-PO
Used to reduce hyperglycemia in type 2 diabetes mellitus
Hypoglycemia, weight gain, fatigue, risk of foot ulcers, headache, skin blisters, tremors, dizziness, and fluid retention.
This drug interacts with thyroid hormones, ACE inhibitors, sulphonylureas, thiazide-like diuretics, corticosteroids and sympathomimetic drugs.
This is contraindicated in patients with type-1 diabetes, severe hepatic disorders, dialysis-dependent severe renal disorders and diabetic ketoacidosis.
Store at 25 to 30°C
303.3993
C17H25N3O2
274901-16-5
